Food Allergy Institute

ALLERGY & IMMUNOLOGY | PROVIDER RESOURCE

Tolerance Induction Program (TIP)

Redefining the standard of care in food allergy treatment

What is TIP?

TIP is a data-driven, precision-medicine protocol designed to achieve lasting remission from multiple food allergies. Using AI-guided dosing and biomarker tracking, TIP retrains the immune system to tolerate allergens without ongoing therapy — moving beyond desensitization to durable immune tolerance.

Why Refer Patients To TIP?

Remission, not just desensitization
Durable immune tolerance after therapy ends

Multi-allergen treatment
Complex, multi-food profiles in one coordinated plan

Nutrition
Expanded diet supports growth, variety, and micronutrient adequacy

Mental health
Reduced daily fear burden; more confidence at school, travel, and social settings

Comorbidity improvement
Patients report improvement in asthma control, eczema flares, and GI inflammation

Inclusive care model
Supports patients with EoE, severe asthma, eczema, and other complex comorbidities

Care Model

Built for real life

- ~90% of the program is completed at home with structured oversight
- Clinic visits focus on supervised challenges, advancement, and biomarker tracking
- Visit cadence: typically every ~8 weeks, ~1 hour

Patient Journey

Referral (simple online form) → Comprehensive evaluation → AI-personalized dosing plan → In-clinic challenges + biomarker tracking → Remission: expanded diet with sustained tolerance

Outcomes

- **Targeted remission timelines:** care plans with a definitive completion date established at launch.
- **99% reach remission** among those who complete the protocol*
- Average treatment time: ~2–4 years for multi-allergen cases

Why TIP Is Different

- No lifelong daily maintenance dosing
- Treats multiple allergens at once
- Built for complex, high-risk cases
- Backed by 200+ trillion data points and thousands of patients
- Ends with safe, unrestricted eating

Advancing Food Allergy Care

TIP vs Avoidance vs OIT vs Xolair

	TIP (Tolerance Induction Program)	Avoidance (Standard of Care)	OIT (Oral Immunotherapy)	Xolair (Omalizumab)
Goal	**Durable remission / sustained tolerance**	Risk management (no immune change)	Desensitization while dosing continues	Reduces allergic reactions after accidental exposure
Allergens	**Multiple simultaneously**	Any (avoid all triggers)	Usually one at a time	Not allergen-specific
Where care happens	**~90% at home + structured oversight**	Daily vigilance	Daily home dosing + supervised dose increases[1]	Injection every 2 or 4 weeks[3]; may transition to self-injection at home for appropriate patients[4]
Visit cadence / time	**Every ~8 weeks, usually ~1 hour**	N/A	Bi-weekly office visits during up-dosing are common[1]; initial dose escalation can take 5–6 hours[2]	Every 2 or 4 weeks[3]
Maintenance	**After remission: gradual step-down; no lifelong daily dosing**	Lifelong avoidance + rescue readiness	Long-term commitment with daily dosing; may continue indefinitely[1]	Ongoing therapy; reassess periodically[3]
Reality Check	**Predictable milestones and check-ins so patients progress safely and steadily (built for working families).**	Exposures still happen. Anxiety stays high. Social limits persist. Nutrition can narrow. Allergy does not change.	Reactions are common during treatment; missed doses reduce the safety margin; ongoing avoidance outside the “protected dose.”[1]	Not for emergency treatment. Avoidance still required. Ongoing injections and coverage friction.[56]

Footnotes (Non-TIP Treatments): [1] AAAAI notes OIT is a long-term commitment requiring daily dosing and commonly bi-weekly office visits during up-dosing. [2] Initial dose escalation can take 5–6 hours (protocol-dependent). [3] FDA label: Xolair dosing every 2 or 4 weeks for IgE-mediated food allergy (dose based on weight and IgE). [4] Self-injection at home may be appropriate for some patients after clinician initiation/training. [5] Xolair should not be used for acute treatment of allergic reactions, including anaphylaxis. [6] FDA approval communication: reduces reactions after accidental exposure; patients must still avoid trigger foods. [7] In a large peanut OIT cohort, 80% experienced likely treatment-related adverse events; >90% occurred at home. [8] PACE: high-certainty evidence shows peanut OIT increases allergic and anaphylactic reactions vs avoidance/placebo. [9] Meta-analysis: adverse events requiring epinephrine in 7.6% of peanut OIT participants. [10] Palforzia OIT manufacturer will discontinue commercialization July 31, 2026 (not related to safety, quality, or efficacy).

Food Allergy Institute

2025 PROGRAM DATA | SAFETY & OUTCOMES

2025 TIP Program Impact & Safety

5,698	1.8M+	33,582	60,643
Patients Seen	At-Home Doses	In-Clinic Challenges	Foods Introduced + Challenged

Safety Snapshot

At-home Reactions: *Self Reported*

Total Reactions (Grade 1+)

0.03% of all at-home doses

Requiring Epinephrine

0.0013% of all at-home doses

Grade 1 (mild): 646 | Grade 2 (moderate): 805 | Grade 3 (severe): 17

In-clinic Reactions: *Challenges*

Total Reactions (Grade 1+)

0.15% of all in-clinic challenges

Requiring Epinephrine

0.0016% of all in-clinic challanges

Grade 1: 68 | Grade 2: 23 | Grade 3: 2
Epinephrine uses in clinic (2025): **1** across 33,000+ challenges

Outcomes

99% reach remission among those who complete the protocol (program-reported). TIP is the largest pediatric food allergy treatment program in the world.

Next Step For Providers

Refer a patient or request clinical data:

Ph/Fax/Text: (562) 512 3640
www.FoodallergyInstitute.com
physicianoutreach@FoodAllergyInstitute.com

Food Allergy Institute

PATIENT REFERRAL | PROVIDER RESOURCE

Provider Referral Program:

How It Works

Partner with the Food Allergy Institute to help patients access life-changing food allergy treatment while supporting education and awareness in your practice.

Getting Started

Step 1: Complete the referral form

- This will generate your unique referral link.

Step 2: Check your inbox

- You'll receive an email confirmation with access to your personalized referral page.

Step 3: Receive your referral toolkit

- Our team will provide the following resources:
  - › Physician Referral Guide & TIP Overview
  - › Anaphylaxis Training Posters (for lobbies, exam rooms, and hallways)
  - › Patient Handouts & Brochures (TIP Overview + free EAI training info)
  - › Food Freedom Cards (to encourage patient engagement)

What Happens After You Refer a Patient

1. Referral Submitted
The patient completes the referral form using your unique link. You receive confirmation once it's submitted.

2. Safety Training Completed
The patient completes complimentary epinephrine auto-injector (EAI) training.

3. Training Confirmation
Both you and the patient receive confirmation upon training completion.

4. Consultation & Care Coordination
Our team schedules the TIP consultation and manages all logistics, including insurance coordination.

5. Program Enrollment & Ongoing Updates
Once enrolled, you receive onboarding confirmation and ongoing updates throughout the patient's treatment.

aetna | Anthem Blue Cross | United Healthcare | Cigna | blue california | health net